Tel:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@anticorps-enligne.fr

PD-L1 anticorps (C-Term)

PD-L1 Reactivité: Humain WB, IHC (p) Hôte: Chèvre Polyclonal unconjugated
N° du produit ABIN374512
  • Antigène Voir toutes PD-L1 Anticorps
    PD-L1 (CD274 (PD-L1))
    Épitope
    • 29
    • 16
    • 15
    • 12
    • 11
    • 9
    • 8
    • 7
    • 7
    • 5
    • 4
    • 3
    • 2
    • 2
    • 2
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    C-Term
    Reactivité
    • 166
    • 108
    • 63
    • 7
    • 6
    • 5
    • 5
    • 1
    • 1
    Humain
    Hôte
    • 126
    • 58
    • 17
    • 4
    • 4
    • 1
    Chèvre
    Clonalité
    • 108
    • 100
    • 2
    Polyclonal
    Conjugué
    • 95
    • 15
    • 13
    • 11
    • 9
    • 5
    • 5
    • 5
    • 5
    • 5
    • 5
    • 5
    • 4
    • 4
    • 4
    • 4
    • 4
    • 4
    • 3
    • 2
    • 1
    • 1
    • 1
    Cet anticorp PD-L1 est non-conjugé
    Application
    • 136
    • 103
    • 57
    • 40
    • 38
    • 28
    • 17
    • 16
    • 16
    • 15
    • 10
    • 7
    • 5
    • 5
    • 3
    • 3
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    Western Blotting (WB), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))
    Séquence
    CKKQSDTHLE ET
    Specificité
    This antibody recognizes Human CD274 / PDL1. Other species not tested.
    Purification
    Ammonium Sulphate Precipitation followed by Antigen Affinity Chromatography using the immunizing peptide
    Immunogène
    Synthetic peptide from the C-Terminus of Human (NP_054862.1) Genename: CD274
    Top Product
    Discover our top product PD-L1 Anticorps primaire
  • Indications d'application
    Peptide ELISA: 1/8000. Western blot: 0.3-1.0 μg/mL. Approx 35 kDa band observed in Human Heart lysates(calculated MW of 33.5 kDa according to NP_054862.1). Immunohistochemistry: 4-6 μg/mL. In paraffin embedded Human Skeletal Muscle shows staining of the striated muscularfibres.
    Other applications not tested.
    Optimal dilutions are dependent on conditions and should be determined by the user.
    Restrictions
    For Research Use only
  • Concentration
    0.5 mg/mL
    Buffer
    Tris saline, pH ~7.3, 0.02 % Sodium Azide, 0.5 % BSA
    Agent conservateur
    Sodium azide
    Précaution d'utilisation
    This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
    Conseil sur la manipulation
    Avoid repeated freezing and thawing.
    Stock
    4 °C/-20 °C
    Stockage commentaire
    Store the antibody undiluted at 2-8 °C for one month or (in aliquots) at -20 °C.
  • Antigène
    PD-L1 (CD274 (PD-L1))
    Autre désignation
    CD274 / PDL1 (PD-L1 Produits)
    Synonymes
    anticorps B7-H, anticorps B7H1, anticorps PD-L1, anticorps PDCD1L1, anticorps PDCD1LG1, anticorps PDL1, anticorps A530045L16Rik, anticorps B7h1, anticorps Pdcd1l1, anticorps Pdcd1lg1, anticorps Pdl1, anticorps RGD1566211, anticorps CD274 molecule, anticorps CD274 antigen, anticorps programmed cell death 1 ligand 2, anticorps CD274, anticorps Cd274, anticorps PDCD1LG2
    Sujet
    CD274 [PDL1] is expressed by antigen presenting cells, including human peripheral blood monocytes stimulated with interferon gamma, and activated human and murine dendritic cells. In addition, PDL1 is expressed in nonlymphoid tissues such as heart and lung. The relative levels of inhibitory PDL1 and costimulatory B7 1/B7 2 signals on antigen presenting cells may determine the extent of T cell activation and consequently the threshold between tolerance and autoimmunity. PDL1 expression on nonlymphoid tissues and its potential interaction with PD1 may subsequently determine the extent of immune responses at sites of inflammation. PDL1 is thought to be involved in fetomaternal tolerance.Synonyms: B7 homolog 1, B7H1, PD-L1, PDCD1 ligand 1, PDCD1L1, PDCD1LG1, Programmed cell death 1 ligand 1, Programmed death ligand 1
    ID gène
    29126, 9606
    UniProt
    Q9NZQ7
    Pathways
    Cancer Immune Checkpoints
Vous êtes ici:
Support technique